Company Description
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.
It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 367 |
| CEO | Marianne De Backer |
Contact Details
Address: 1800 Owens Street, Suite 900 San Francisco, California 94158 United States | |
| Phone | 415 906 4324 |
| Website | vir.bio |
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| Employer ID | 81-2730369 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | Chief Executive Officer and Director |
| Jason O'Byrne M.B.A. | Executive Vice President and Chief Financial Officer |
| Vanina de Verneuil J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Mark D. Eisner M.D., M.P.H. | Executive Vice President and Chief Medical Officer |
| Dr. Lawrence Corey M.D. | Co-Founder and Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder and Scientific Advisor |
| Brent Sabatini | Senior Vice President, Principal Accounting Officer and Chief Accounting Officer |
| Dr. Maninder Hora Ph.D. | Executive Vice President and Chief Technical Operations Officer |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Kiki Patel Pharm.D. | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 8-K | Current Report |
| Mar 3, 2026 | SCHEDULE 13D/A | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 424B5 | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 24, 2026 | 144 | Filing |